Enovis Corporation (ENOV) Income Statement

NYSE: ENOVRevenue, profits, margins and EPS over 10 years.

ENOV 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+6.7%
$2.25B
2025 · hover or tap a bar for each year
2016: $3.65B (−8.1%)2017: $3.30B (−9.5%)2018: $2.19B (−33.5%)2019: $3.33B (+51.7%)2020: $3.07B (−7.7%)2021: $1.43B (−53.6%)2022: $1.56B (+9.6%)2023: $1.71B (+9.2%)2024: $2.11B (+23.5%)2025: $2.25B (+6.7%)
20162025
Gross profit+13.9%
$1.35B
2025 · hover or tap a bar for each year
2016: $1.15B (−8.5%)2017: $1.03B (−10.1%)2018: $729.4M (−29.2%)2019: $1.40B (+92.1%)2020: $1.29B (−8.1%)2021: $777.7M (−39.6%)2022: $869.4M (+11.8%)2023: $990.8M (+14.0%)2024: $1.18B (+19.2%)2025: $1.35B (+13.9%)
20162025
Operating income
−$18.9M
2025 · hover or tap a bar for each year
2016: $238.0M (−16.4%)2017: $29.2M (−87.8%)2018: $151.5M (+419.8%)2019: $203.6M (+34.4%)2020: $162.3M (−20.3%)2021: −$62.8M (−138.7%)2022: −$71.2M2023: −$65.7M2024: −$775.7M2025: −$18.9M
20162025
Net income
−$1.18B
2025 · hover or tap a bar for each year
2016: $128.1M (−23.6%)2017: $151.1M (+17.9%)2018: $140.2M (−7.2%)2019: −$527.6M (−476.4%)2020: $42.6M2021: $71.7M (+68.1%)2022: −$13.3M (−118.5%)2023: −$33.3M2024: −$825.5M2025: −$1.18B
20162025
EPS (diluted)+16.6%
$3.30
2025 · hover or tap a bar for each year
2016: $4.68 (−3.1%)2017: $4.95 (+5.8%)2018: $6.96 (+40.6%)2019: $6.54 (−6.0%)2020: $4.17 (−36.2%)2021: $6.39 (+53.2%)2022: $2.27 (−64.5%)2023: $2.40 (+5.7%)2024: $2.83 (+17.9%)2025: $3.30 (+16.6%)
20162025
Net profit margin−13.5 pts
−52.7%
2025 · hover or tap a point for each year
2016: 3.5% (−0.7 pts)2017: 4.6% (+1.1 pts)2018: 6.4% (+1.8 pts)2019: −15.9% (−22.2 pts)2020: 1.4% (+17.2 pts)2021: 5.0% (+3.6 pts)2022: −0.9% (−5.9 pts)2023: −1.9% (−1.1 pts)2024: −39.2% (−37.2 pts)2025: −52.7% (−13.5 pts)
20162025

ENOV revenue and net income

RevenueNet incomeNet margin (right axis)

Where ENOV's revenue goes

2025
Revenue
$2.25B100.0%
Cost of revenue
−$902.8M−40.2%
Gross profit
$1.35B59.8%
Research & development
−$120.3M−5.4%
Sales, general & admin
−$1.07B−47.6%
Other operating expenses
−$173.6M−7.7%
Operating income
−$18.9M−0.8%
Interest & other expense
−$1.14B−50.7%
Income taxes
−$22.3M−1.0%
Net income
−$1.18B−52.7%

Each bar shows an amount and its share of revenue. ENOV kept −52.7% of revenue as net income.

ENOV profit margins

GrossOperatingNet

ENOV growth rates

to 2025
1 year3 years5 years10 years
Revenue+6.7%+12.9%−6.0%−5.5%
Gross profit+13.9%+15.7%+0.9%+0.7%
Operating income————
Net income————
EPS (diluted)+16.6%+13.3%−4.6%−3.7%

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

ENOV quarterly EPS vs estimates

Reported EPSAnalyst estimate

Enovis beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $0.64).

ENOV income statement

Enovis Corporation annual income statement
2025202420232022202120202019201820172016
Revenue$2.25B$2.11B$1.71B$1.56B$1.43B$3.07B$3.33B$2.19B$3.30B$3.65B
Cost of revenue$902.8M$926.9M$716.4M$693.7M$648.5M$1.78B$1.93B$1.46B$2.27B$2.50B
Gross profit$1.35B$1.18B$990.8M$869.4M$777.7M$1.29B$1.40B$729.4M$1.03B$1.15B
Research & development$120.3M$91.3M$75.3M$60.8M$49.1M$34.3M$61.8M$34.2M$42.9M$39.3M
Sales, general & admin$1.07B$1.03B$830.3M$772.9M$1.33B$1.09B$1.13B$818.2M——
Total operating expenses$1.36B$1.96B$1.06B$940.6M$840.5M$1.13B$1.20B$577.8M$732.3M$825.2M
Operating income−$18.9M−$775.7M−$65.7M−$71.2M−$62.8M$162.3M$203.6M$151.5M$29.2M$238.0M
Interest expense$34.8M$57.1M$19.7M$25.0M$29.1M$52.8M$119.5M$49.1M$40.1M$30.0M
Income before taxes−$1.16B−$822.9M−$67.1M−$2.1M−$121.8M$58.0M$50.5M$182.8M−$12.0M$208.0M
Income taxes$22.3M$4.5M−$13.3M$36.1M−$19.5M−$6.1M$31.6M−$21,000$42.6M$62.8M
Net income−$1.18B−$825.5M−$33.3M−$13.3M$71.7M$42.6M−$527.6M$140.2M$151.1M$128.1M
EBITDA−$830.2M−$481.0M$169.7M$241.7M$170.2M$180.0M$406.0M$330.3M$160.4M$349.3M
EPS (diluted)$3.30$2.83$2.40$2.27$6.39$4.17$6.54$6.96$4.95$4.68
Gross margin59.8%56.0%58.0%55.6%54.5%41.9%42.1%33.3%31.2%31.4%
Operating margin−0.8%−36.8%−3.8%−4.6%−4.4%5.3%6.1%6.9%0.9%6.5%
Net margin−52.7%−39.2%−1.9%−0.9%5.0%1.4%−15.9%6.4%4.6%3.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ENOV's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

ENOV financial results

In fiscal year 2025 (ended December 31, 2025), Enovis reported revenue of $2.2 billion, up 6.7% from the year before. It had a net loss of $1.2 billion, a net profit margin of −52.7%. Diluted earnings per share came to $3.30. Over five years revenue grew at an average rate of −6.0% a year.

See the ENOV stock overview for the latest quote and news, or the ENOV chart for price history and technical indicators.

ENOV income statement FAQ

What is Enovis's annual revenue?

Enovis reported total revenue of $2.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 6.7% from $2.1 billion the previous year.

Is Enovis profitable?

No. Enovis reported a net loss of $1.2 billion in fiscal 2025, a net profit margin of −52.7%; its operating margin was −0.8%.

What is Enovis's gross margin?

Enovis's gross margin was 59.8% in fiscal 2025: for every $100 of revenue, Enovis kept $60 after the direct cost of its products and services.

How much does Enovis spend on research and development?

Enovis spent $120.3 million on research and development in fiscal 2025, 5.4% of revenue.

How fast is Enovis growing?

Revenue grew −6.0% a year on average over the last five fiscal years, from $3.1 billion to $2.2 billion.

What are Enovis's earnings per share?

Enovis earned $3.30 per diluted share in fiscal 2025, compared with $2.83 a year earlier.

When will Enovis report its next earnings?

Enovis is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.

When does Enovis's fiscal year end?

Enovis's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.

Medical Devices income statements